26.08.2015 - In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.
The Bio-Based Industries Joint Undertaking (BBI JU) aims to research innovative ways of using renewable resources. For its second call for proposals, the partnership has released €106m. “The call for proposals is aimed at speeding up the development of new biorefineries. Moreover, it is focused on exploiting synergies across sectors. This means new business models that integrate economic actors all along the entire value chain,” the BBI said in their statement.
The bulk of the budget for the proposals will go to Demonstration Action, focusing on intermediary and end products made from biological sources. The rest will go to fundamental research and innovation in biorefinery technology. One of the challenges being tackled is pre-treating lingocellulose while removing contaminants and separating lignin and cellulosic fractions. “Solving this challenge will remove a major hurdle to processing biomass into feedstock,” BBI commented. Another project seeks to engineer a tree species that will generate wood specifically designed for industrial processing. And yet another aims to bring down the extraction and conversion costs for resources obtained from algae and microalgae.
The deadline for proposal submission is December 2015. The first call worth €100m focused on flagships and runs until mid-September. BBI JU was launched in July 2014 as a €3.7bn public-private partnership between the EU and the Bio-based Industries Consortium.
25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.
21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.
11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.
04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more